UPDATE: Wedbush Downgrades Delcath Systems to Neutral Following Negative ODAC Vote
May 03, 2013 at 10:24 AM EDT
In a report published Friday, Wedbush analyst Gregory R. Wade downgraded the rating on Delcath Systems (NASDAQ: DCTH ) from Outperform to Neutral, and lowered the price target from $5.00 to $1.30. In the report, Wade noted, “Delcath's liver-specific chemotherapy drug device combination product (CHEMOSAT – EU, Melblez – US)
